Suven Life Sciences Limited Q1 FY26 results press release summary

Results press release of 13 Aug 2025, summarised by AI from the filing.

Suven Life Sciences reports Q1 FY26 net loss of ₹515.17 mn and completes ₹8,576.40 mn fund raising via convertible warrants.

Key takeaways

1. Fund raising Completed ₹8,576.40 mn fund raising via 64,002,999 convertible warrants at ₹134 per warrant.
2. SUVN-911 Phase 2B study initiated in USA; enrollment started July-2025; anticipated completion FY27.
3. Risk Clinical development outcome and dependence on collaborative programs may cause results to differ.

Original filing on BSE

Suven Life Sciences Limited Q1 FY27 results

As filed: Revenue ₹3.6 cr, EBITDA −₹132 cr, PAT −₹128 cr, EBITDA margin -3711.2%.

Not scored. Too small to score: quarter revenue ₹3.6 cr is below the ₹20.0 cr minimum. On a base this small, percentage changes say little.

Earlier results and the share price after them

• Q4 FY26: Revenue ₹1.5 cr, EBITDA −₹50.6 cr, PAT −₹45.6 cr, EBITDA margin -3331.6%. Not scored. Too small to score: quarter revenue ₹1.5 cr is below the ₹20.0 cr minimum. On a base this small, percentage changes say little. Share price after the results: +24.0% in 30 days (Nifty 500: +1.3%).
• Q3 FY26: Revenue ₹2.8 cr, EBITDA −₹103 cr, PAT −₹102 cr, EBITDA margin -3677.6%. Not scored. Too small to score: quarter revenue ₹2.8 cr is below the ₹20.0 cr minimum. On a base this small, percentage changes say little. Share price after the results: +5.5% in 29 days (Nifty 500: +0.4%).
• Q2 FY26: Revenue ₹1.0 cr, EBITDA −₹80.0 cr, PAT −₹77.0 cr, EBITDA margin -8000.0%. Not scored. Too small to score: quarter revenue ₹1.0 cr is below the ₹20.0 cr minimum. On a base this small, percentage changes say little. Share price after the results: −10.2% in 30 days (Nifty 500: −0.2%).
• Q1 FY26: Revenue ₹2.0 cr, EBITDA −₹52.0 cr, PAT −₹52.0 cr, EBITDA margin -2600.0%. Not scored. Too small to score: quarter revenue ₹2.0 cr is below the ₹20.0 cr minimum. On a base this small, percentage changes say little. Share price after the results: −3.7% in 30 days (Nifty 500: +2.8%).
• Q4 FY25: Revenue ₹1.0 cr, EBITDA −₹44.0 cr, PAT −₹44.0 cr, EBITDA margin -4400.0%. Not scored. Too small to score: quarter revenue ₹1.0 cr is below the ₹20.0 cr minimum. On a base this small, percentage changes say little. Share price after the results: +52.1% in 30 days (Nifty 500: +3.1%).
• Q3 FY25: Revenue ₹2.0 cr, EBITDA −₹39.0 cr, PAT −₹39.0 cr, EBITDA margin -1950.0%. Not scored. Too small to score: quarter revenue ₹2.0 cr is below the ₹20.0 cr minimum. On a base this small, percentage changes say little.
• Q2 FY25: Revenue ₹3.0 cr, EBITDA −₹53.0 cr, PAT −₹50.0 cr, EBITDA margin -1766.7%. Not scored. Too small to score: quarter revenue ₹3.0 cr is below the ₹20.0 cr minimum. On a base this small, percentage changes say little.

Past price moves after results do not indicate future moves. Not a recommendation.

Suven Life Sciences Limited earnings call, investor presentation and press release summaries

• Q1 FY26: Results press release (13 Aug 2025)